DBV Technologies reported $-33.48M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Galectin Therapeutics USD -7.42M 819K Dec/2021
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Incyte USD 414.5M 92.42M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
United Therapeutics USD 436.8M 34.2M Jun/2025